RedHill Biopharma COO acquires 27.6M depositary shares

Each ADS is convertible at any time at the holder’s election, for no consideration, and has no expiration date.

Rhea-AI Filing Summary

RedHill Biopharma Ltd. Chief Operating Officer Gilead Raday reported acquiring 27,560,000 American Depository Shares through a derivative conversion on October 1, 2026; 131,690,000 American Depository Shares were reported following that entry. On the same date, a trustee sold 1,431 ADS, representing 14,310,000 ordinary shares, at $0.465 per ADS ($0.0000465 per ordinary share) to satisfy tax withholding on vesting of 4,187 RSUs. The sale was under a sell-to-cover policy and was not a discretionary trade by Raday; 176,910,000 ordinary shares were reported following the sale.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 2 txns

Insider Raday Gilead

Role Chief Operating Officer

Sold 14,310,000 shs ($1K)

Approx. gross sale proceeds $1K

Type	Security	Shares	Price	Value
Exercise	American Depository Shares F3	27,560,000	$0.00	$0.00
Sale	Ordinary Shares F1, F2	14,310,000	$0.0001	$1K

Holdings After Transaction: American Depository Shares — 131,690,000 contracts (Direct); Ordinary Shares — 176,910,000 shares (Direct)

Footnotes (3)

1. F1. The reporting person sold 1,431 American Depository Shares ("ADS"), of RedHill Biopharma Ltd. (the "Issuer"), each ADS represents 10,000 ordinary shares, which have no par value effective August 7, 2026, solely to satisfy tax withholding obligations incurred upon the vesting of an aggregate of 4,187 Restricted Share Units ("RSU") granted to him on March 26, 2025, and January 23, 2026. Such transaction was effected by the trustee appointed in accordance with the regulations set by the Israeli Tax Authority pursuant to a sell to cover policy and does not represent a discretionary trade by the reporting person.
2. F2. The price reported in Table 1 Column 4 is $0.465 per ADS, which would be equivalent to $0.0000465 per ordinary share.
3. F3. Each ADS is convertible at any time, at the holder's election, for no consideration and has no expiration date.

Key Figures

American Depository Shares acquired through derivative conversion: 27,560,000 shares American Depository Shares following conversion entry: 131,690,000 shares American Depository Shares sold: 1,431 shares +4 more

7 metrics

American Depository Shares acquired through derivative conversion 27,560,000 shares October 1, 2026

American Depository Shares following conversion entry 131,690,000 shares Reported following the October 1, 2026 transaction

American Depository Shares sold 1,431 shares October 1, 2026

Ordinary shares represented by ADS sold 14,310,000 shares October 1, 2026

Sale price $0.465 per ADS Equivalent to $0.0000465 per ordinary share

Ordinary shares following reported sale 176,910,000 shares Reported following the October 1, 2026 transaction

Restricted Share Units vested 4,187 RSUs Granted March 26, 2025, and January 23, 2026

Key Terms

American Depository Shares, Restricted Share Units, sell to cover policy

3 terms

American Depository Shares financial

"1,431 American Depository Shares ("ADS")"

American depository shares are U.S.-listed securities that stand in for a foreign company’s ordinary shares, held by a U.S. bank which issues the ADS so investors can trade the foreign stock in U.S. dollars and on U.S. exchanges. Think of them like a locally wrapped version of a foreign product—easier to buy and sell at home—but they still carry risks from currency differences, foreign rules and potential limits on voting rights, so they affect access, liquidity and investment risk.

Restricted Share Units financial

"aggregate of 4,187 Restricted Share Units ("RSU")"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

sell to cover policy financial

"pursuant to a sell to cover policy"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RDHL shares did Gilead Raday sell, and at what price?

The sale covered 1,431 American Depository Shares (ADS), representing 14,310,000 ordinary shares, at $0.465 per ADS, equivalent to $0.0000465 per ordinary share. No Rule 10b5-1 plan is reported.

Why were RDHL ADS sold, and which RSUs were involved?

A trustee sold the ADS to satisfy tax withholding obligations incurred upon vesting of an aggregate of 4,187 Restricted Share Units granted on March 26, 2025, and January 23, 2026. The sale was effected under a sell-to-cover policy.

How can RedHill ADSs be converted?

Each ADS is convertible at any time, at the holder’s election, for no consideration, and has no expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/06/2026 - 07:00 AM Accepted by SEC EDGAR 10/06/2026 - 07:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Raday Gilead

(Last) (First) (Middle)

21 HA'ARBA'A STREET

(Street)

TEL AVIV 6473921

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
RedHill Biopharma Ltd. [ RDHL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	10/01/2026		S(1)		14,310,000(1)	D	$0.0001(2)	176,910,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depository Shares	(3)	10/01/2026		M		27,560,000		(3)	(3)	Ordinary Shares	27,560,000	$0	131,690,000	D

Explanation of Responses:

1. The reporting person sold 1,431 American Depository Shares ("ADS"), of RedHill Biopharma Ltd. (the "Issuer"), each ADS represents 10,000 ordinary shares, which have no par value effective August 7, 2026, solely to satisfy tax withholding obligations incurred upon the vesting of an aggregate of 4,187 Restricted Share Units ("RSU") granted to him on March 26, 2025, and January 23, 2026. Such transaction was effected by the trustee appointed in accordance with the regulations set by the Israeli Tax Authority pursuant to a sell to cover policy and does not represent a discretionary trade by the reporting person.

2. The price reported in Table 1 Column 4 is $0.465 per ADS, which would be equivalent to $0.0000465 per ordinary share.

3. Each ADS is convertible at any time, at the holder's election, for no consideration and has no expiration date.

	/s/ Gilead Raday	10/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)